Physician profile
Alister George
NPI 1821280629
$5,577.75
in general payments reported to CMS, 2019-2025
32 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $229 · 2021: $669 · 2022: $914 · 2023: $744 · 2024: $1,069 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,430.50 | 2019-2025 | |
| Janssen Biotech, INC. | $750.16 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $535.01 | 2022-2025 | Dupixent |
| Pfizer INC. | $418.96 | 2021-2025 | |
| Genzyme Corporation | $291.35 | 2022-2025 | |
| Qol Medical, LLC | $284.99 | 2019-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $189.79 | 2020-2025 | Captivator II |
| Phathom Pharmaceuticals, INC. | $186.19 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $123.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $110.79 | 2021-2023 | Gimoti |
| Braintree Laboratories, INC. | $110.02 | 2022-2023 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.89 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $104.18 | 2025 | |
| Redhill Biopharma INC. | $99.71 | 2020-2021 | |
| Novo Nordisk INC | $93.25 | 2024-2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $90.36 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $71.77 | 2022 | |
| Vivus LLC | $67.71 | 2023-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $65.31 | 2024-2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $61.94 | 2021-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $61.54 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $49.78 | 2024-2025 | Rebyota |
| Allergan, INC. | $42.39 | 2019 | |
| Intercept Pharmaceuticals, INC. | $39.44 | 2020-2022 | |
| Ardelyx, INC. | $32.41 | 2024 | Ibsrela |
| Lilly USA, LLC | $29.94 | 2025 | Omvoh |
| Ucb, INC. | $24.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.21 | 2025 | Iqirvo |
| Conmed Corporation | $21.93 | 2022 | |
| Merck Sharp & Dohme LLC | $20.64 | 2022 | |
| Lucid Diagnostics INC. | $18.28 | 2023 | |
| Concordia Pharmaceuticals INC. | $17.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alister George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.